Global Targeted Drugs for NSCLC Market Size, Status and Forecast 2024-2031

Report ID: 918283 | Published Date: Jan 2025 | No. of Page: 128 | Base Year: 2024 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Target EGFR
        1.2.3 Target ALK
        1.2.4 Target HER2
        1.2.5 Target ROS1
        1.2.6 Target BRAF
        1.2.7 Target MEK
        1.2.8 Target VEGFR2
        1.2.9 Target VEGF
        1.2.10 Target MET
    1.3 Market by Application
        1.3.1 Global Targeted Drugs for NSCLC Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Squamous Cell Carcinoma of NSCLC
        1.3.3 Adenocarcinoma of NSCLC
        1.3.4 Large Cell Carcinoma of NSCLC
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Targeted Drugs for NSCLC Market Perspective (2016-2027)
    2.2 Targeted Drugs for NSCLC Growth Trends by Regions
        2.2.1 Targeted Drugs for NSCLC Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Targeted Drugs for NSCLC Historic Market Share by Regions (2016-2021)
        2.2.3 Targeted Drugs for NSCLC Forecasted Market Size by Regions (2022-2027)
    2.3 Targeted Drugs for NSCLC Industry Dynamic
        2.3.1 Targeted Drugs for NSCLC Market Trends
        2.3.2 Targeted Drugs for NSCLC Market Drivers
        2.3.3 Targeted Drugs for NSCLC Market Challenges
        2.3.4 Targeted Drugs for NSCLC Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Targeted Drugs for NSCLC Players by Revenue
        3.1.1 Global Top Targeted Drugs for NSCLC Players by Revenue (2016-2021)
        3.1.2 Global Targeted Drugs for NSCLC Revenue Market Share by Players (2016-2021)
    3.2 Global Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Targeted Drugs for NSCLC Revenue
    3.4 Global Targeted Drugs for NSCLC Market Concentration Ratio
        3.4.1 Global Targeted Drugs for NSCLC Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for NSCLC Revenue in 2020
    3.5 Targeted Drugs for NSCLC Key Players Head office and Area Served
    3.6 Key Players Targeted Drugs for NSCLC Product Solution and Service
    3.7 Date of Enter into Targeted Drugs for NSCLC Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Targeted Drugs for NSCLC Breakdown Data by Type
    4.1 Global Targeted Drugs for NSCLC Historic Market Size by Type (2016-2021)
    4.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2022-2027)

5 Targeted Drugs for NSCLC Breakdown Data by Application
    5.1 Global Targeted Drugs for NSCLC Historic Market Size by Application (2016-2021)
    5.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Targeted Drugs for NSCLC Market Size (2016-2027)
    6.2 North America Targeted Drugs for NSCLC Market Size by Type
        6.2.1 North America Targeted Drugs for NSCLC Market Size by Type (2016-2021)
        6.2.2 North America Targeted Drugs for NSCLC Market Size by Type (2022-2027)
        6.2.3 North America Targeted Drugs for NSCLC Market Size by Type (2016-2027)
    6.3 North America Targeted Drugs for NSCLC Market Size by Application
        6.3.1 North America Targeted Drugs for NSCLC Market Size by Application (2016-2021)
        6.3.2 North America Targeted Drugs for NSCLC Market Size by Application (2022-2027)
        6.3.3 North America Targeted Drugs for NSCLC Market Size by Application (2016-2027)
    6.4 North America Targeted Drugs for NSCLC Market Size by Country
        6.4.1 North America Targeted Drugs for NSCLC Market Size by Country (2016-2021)
        6.4.2 North America Targeted Drugs for NSCLC Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Targeted Drugs for NSCLC Market Size (2016-2027)
    7.2 Europe Targeted Drugs for NSCLC Market Size by Type
        7.2.1 Europe Targeted Drugs for NSCLC Market Size by Type (2016-2021)
        7.2.2 Europe Targeted Drugs for NSCLC Market Size by Type (2022-2027)
        7.2.3 Europe Targeted Drugs for NSCLC Market Size by Type (2016-2027)
    7.3 Europe Targeted Drugs for NSCLC Market Size by Application
        7.3.1 Europe Targeted Drugs for NSCLC Market Size by Application (2016-2021)
        7.3.2 Europe Targeted Drugs for NSCLC Market Size by Application (2022-2027)
        7.3.3 Europe Targeted Drugs for NSCLC Market Size by Application (2016-2027)
    7.4 Europe Targeted Drugs for NSCLC Market Size by Country
        7.4.1 Europe Targeted Drugs for NSCLC Market Size by Country (2016-2021)
        7.4.2 Europe Targeted Drugs for NSCLC Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Targeted Drugs for NSCLC Market Size (2016-2027)
    8.2 Asia-Pacific Targeted Drugs for NSCLC Market Size by Type
        8.2.1 Asia-Pacific Targeted Drugs for NSCLC Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Targeted Drugs for NSCLC Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Targeted Drugs for NSCLC Market Size by Type (2016-2027)
    8.3 Asia-Pacific Targeted Drugs for NSCLC Market Size by Application
        8.3.1 Asia-Pacific Targeted Drugs for NSCLC Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Targeted Drugs for NSCLC Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Targeted Drugs for NSCLC Market Size by Application (2016-2027)
    8.4 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region
        8.4.1 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Targeted Drugs for NSCLC Market Size (2016-2027)
    9.2 Latin America Targeted Drugs for NSCLC Market Size by Type
        9.2.1 Latin America Targeted Drugs for NSCLC Market Size by Type (2016-2021)
        9.2.2 Latin America Targeted Drugs for NSCLC Market Size by Type (2022-2027)
        9.2.3 Latin America Targeted Drugs for NSCLC Market Size by Type (2016-2027)
    9.3 Latin America Targeted Drugs for NSCLC Market Size by Application
        9.3.1 Latin America Targeted Drugs for NSCLC Market Size by Application (2016-2021)
        9.3.2 Latin America Targeted Drugs for NSCLC Market Size by Application (2022-2027)
        9.3.3 Latin America Targeted Drugs for NSCLC Market Size by Application (2016-2027)
    9.4 Latin America Targeted Drugs for NSCLC Market Size by Country
        9.4.1 Latin America Targeted Drugs for NSCLC Market Size by Country (2016-2021)
        9.4.2 Latin America Targeted Drugs for NSCLC Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Targeted Drugs for NSCLC Market Size (2016-2027)
    10.2 Middle East & Africa Targeted Drugs for NSCLC Market Size by Type
        10.2.1 Middle East & Africa Targeted Drugs for NSCLC Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Targeted Drugs for NSCLC Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Targeted Drugs for NSCLC Market Size by Type (2016-2027)
    10.3 Middle East & Africa Targeted Drugs for NSCLC Market Size by Application
        10.3.1 Middle East & Africa Targeted Drugs for NSCLC Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Targeted Drugs for NSCLC Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Targeted Drugs for NSCLC Market Size by Application (2016-2027)
    10.4 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country
        10.4.1 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Allergan
        11.1.1 Allergan Company Details
        11.1.2 Allergan Business Overview
        11.1.3 Allergan Targeted Drugs for NSCLC Introduction
        11.1.4 Allergan Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.1.5 Allergan Recent Development
    11.2 Amgen
        11.2.1 Amgen Company Details
        11.2.2 Amgen Business Overview
        11.2.3 Amgen Targeted Drugs for NSCLC Introduction
        11.2.4 Amgen Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.2.5 Amgen Recent Development
    11.3 ARIAD Pharmaceuticals (Takeda)
        11.3.1 ARIAD Pharmaceuticals (Takeda) Company Details
        11.3.2 ARIAD Pharmaceuticals (Takeda) Business Overview
        11.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Introduction
        11.3.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.3.5 ARIAD Pharmaceuticals (Takeda) Recent Development
    11.4 Beacon Pharma Limited
        11.4.1 Beacon Pharma Limited Company Details
        11.4.2 Beacon Pharma Limited Business Overview
        11.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Introduction
        11.4.4 Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.4.5 Beacon Pharma Limited Recent Development
    11.5 BeiGene
        11.5.1 BeiGene Company Details
        11.5.2 BeiGene Business Overview
        11.5.3 BeiGene Targeted Drugs for NSCLC Introduction
        11.5.4 BeiGene Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.5.5 BeiGene Recent Development
    11.6 Biocon
        11.6.1 Biocon Company Details
        11.6.2 Biocon Business Overview
        11.6.3 Biocon Targeted Drugs for NSCLC Introduction
        11.6.4 Biocon Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.6.5 Biocon Recent Development
    11.7 Boehringer-Ingelheim
        11.7.1 Boehringer-Ingelheim Company Details
        11.7.2 Boehringer-Ingelheim Business Overview
        11.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Introduction
        11.7.4 Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.7.5 Boehringer-Ingelheim Recent Development
    11.8 Celgene Corporation
        11.8.1 Celgene Corporation Company Details
        11.8.2 Celgene Corporation Business Overview
        11.8.3 Celgene Corporation Targeted Drugs for NSCLC Introduction
        11.8.4 Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.8.5 Celgene Corporation Recent Development
    11.9 Drug International Limted
        11.9.1 Drug International Limted Company Details
        11.9.2 Drug International Limted Business Overview
        11.9.3 Drug International Limted Targeted Drugs for NSCLC Introduction
        11.9.4 Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.9.5 Drug International Limted Recent Development
    11.10 Fujifilm Kyowa Kirin Biologics
        11.10.1 Fujifilm Kyowa Kirin Biologics Company Details
        11.10.2 Fujifilm Kyowa Kirin Biologics Business Overview
        11.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Introduction
        11.10.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.10.5 Fujifilm Kyowa Kirin Biologics Recent Development
    11.11 Genvio Pharma Limited
        11.11.1 Genvio Pharma Limited Company Details
        11.11.2 Genvio Pharma Limited Business Overview
        11.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Introduction
        11.11.4 Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.11.5 Genvio Pharma Limited Recent Development
    11.12 Hetero Drugs
        11.12.1 Hetero Drugs Company Details
        11.12.2 Hetero Drugs Business Overview
        11.12.3 Hetero Drugs Targeted Drugs for NSCLC Introduction
        11.12.4 Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.12.5 Hetero Drugs Recent Development
    11.13 ImClone Systems ‎(Eli Lilly)
        11.13.1 ImClone Systems ‎(Eli Lilly) Company Details
        11.13.2 ImClone Systems ‎(Eli Lilly) Business Overview
        11.13.3 ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Introduction
        11.13.4 ImClone Systems ‎(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.13.5 ImClone Systems ‎(Eli Lilly) Recent Development
    11.14 Incepta Pharmaceuticals
        11.14.1 Incepta Pharmaceuticals Company Details
        11.14.2 Incepta Pharmaceuticals Business Overview
        11.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Introduction
        11.14.4 Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.14.5 Incepta Pharmaceuticals Recent Development
    11.15 Mylan
        11.15.1 Mylan Company Details
        11.15.2 Mylan Business Overview
        11.15.3 Mylan Targeted Drugs for NSCLC Introduction
        11.15.4 Mylan Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.15.5 Mylan Recent Development
    11.16 Novartis
        11.16.1 Novartis Company Details
        11.16.2 Novartis Business Overview
        11.16.3 Novartis Targeted Drugs for NSCLC Introduction
        11.16.4 Novartis Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.16.5 Novartis Recent Development
    11.17 Pfizer
        11.17.1 Pfizer Company Details
        11.17.2 Pfizer Business Overview
        11.17.3 Pfizer Targeted Drugs for NSCLC Introduction
        11.17.4 Pfizer Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.17.5 Pfizer Recent Development
    11.18 Reliance Lifesciences
        11.18.1 Reliance Lifesciences Company Details
        11.18.2 Reliance Lifesciences Business Overview
        11.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Introduction
        11.18.4 Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.18.5 Reliance Lifesciences Recent Development
    11.18 Roche
        11.25.1 Roche Company Details
        11.25.2 Roche Business Overview
        11.25.3 Roche Targeted Drugs for NSCLC Introduction
        11.25.4 Roche Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.25.5 Roche Recent Development
    11.20 AstraZeneca
        11.20.1 AstraZeneca Company Details
        11.20.2 AstraZeneca Business Overview
        11.20.3 AstraZeneca Targeted Drugs for NSCLC Introduction
        11.20.4 AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.20.5 AstraZeneca Recent Development
    11.21 Cipla
        11.21.1 Cipla Company Details
        11.21.2 Cipla Business Overview
        11.21.3 Cipla Targeted Drugs for NSCLC Introduction
        11.21.4 Cipla Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.21.5 Cipla Recent Development
    11.22 Teva
        11.22.1 Teva Company Details
        11.22.2 Teva Business Overview
        11.22.3 Teva Targeted Drugs for NSCLC Introduction
        11.22.4 Teva Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.22.5 Teva Recent Development
    11.23 OSI Pharmaceuticals
        11.23.1 OSI Pharmaceuticals Company Details
        11.23.2 OSI Pharmaceuticals Business Overview
        11.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Introduction
        11.23.4 OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.23.5 OSI Pharmaceuticals Recent Development
    11.24 Glenmark Pharmaceuticals
        11.24.1 Glenmark Pharmaceuticals Company Details
        11.24.2 Glenmark Pharmaceuticals Business Overview
        11.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Introduction
        11.24.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.24.5 Glenmark Pharmaceuticals Recent Development
    11.25 Natco Pharma
        11.25.1 Natco Pharma Company Details
        11.25.2 Natco Pharma Business Overview
        11.25.3 Natco Pharma Targeted Drugs for NSCLC Introduction
        11.25.4 Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2016-2021)
        11.25.5 Natco Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Targeted Drugs for NSCLC Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Target EGFR
    Table 3. Key Players of Target ALK
    Table 4. Key Players of Target HER2
    Table 5. Key Players of Target ROS1
    Table 6. Key Players of Target BRAF
    Table 7. Key Players of Target MEK
    Table 8. Key Players of Target VEGFR2
    Table 9. Key Players of Target VEGF
    Table 10. Key Players of Target MET
    Table 11. Global Targeted Drugs for NSCLC Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 12. Global Targeted Drugs for NSCLC Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 13. Global Targeted Drugs for NSCLC Market Size by Regions (2016-2021) & (US$ Million)
    Table 14. Global Targeted Drugs for NSCLC Market Share by Regions (2016-2021)
    Table 15. Global Targeted Drugs for NSCLC Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 16. Global Targeted Drugs for NSCLC Market Share by Regions (2022-2027)
    Table 17. Targeted Drugs for NSCLC Market Trends
    Table 18. Targeted Drugs for NSCLC Market Drivers
    Table 19. Targeted Drugs for NSCLC Market Challenges
    Table 20. Targeted Drugs for NSCLC Market Restraints
    Table 21. Global Targeted Drugs for NSCLC Revenue by Players (2016-2021) & (US$ Million)
    Table 22. Global Targeted Drugs for NSCLC Market Share by Players (2016-2021)
    Table 23. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for NSCLC as of 2020)
    Table 24. Ranking of Global Top Targeted Drugs for NSCLC Companies by Revenue (US$ Million) in 2020
    Table 25. Global 5 Largest Players Market Share by Targeted Drugs for NSCLC Revenue (CR5 and HHI) & (2016-2021)
    Table 26. Key Players Headquarters and Area Served
    Table 27. Key Players Targeted Drugs for NSCLC Product Solution and Service
    Table 28. Date of Enter into Targeted Drugs for NSCLC Market
    Table 29. Mergers & Acquisitions, Expansion Plans
    Table 30. Global Targeted Drugs for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 31. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2016-2021)
    Table 32. Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 33. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 34. Global Targeted Drugs for NSCLC Market Size Share by Application (2016-2021) & (US$ Million)
    Table 35. Global Targeted Drugs for NSCLC Revenue Market Share by Application (2016-2021)
    Table 36. Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 37. Global Targeted Drugs for NSCLC Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 38. North America Targeted Drugs for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 39. North America Targeted Drugs for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 40. North America Targeted Drugs for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 41. North America Targeted Drugs for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 42. North America Targeted Drugs for NSCLC Market Size by Country (2016-2021) & (US$ Million) 
    Table 43. North America Targeted Drugs for NSCLC Market Size by Country (2022-2027) & (US$ Million) 
    Table 44. Europe Targeted Drugs for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 45. Europe Targeted Drugs for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 46. Europe Targeted Drugs for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 47. Europe Targeted Drugs for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 48. Europe Targeted Drugs for NSCLC Market Size by Country (2016-2021) & (US$ Million) 
    Table 49. Europe Targeted Drugs for NSCLC Market Size by Country (2022-2027) & (US$ Million) 
    Table 50. Asia-Pacific Targeted Drugs for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 51. Asia-Pacific Targeted Drugs for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 52. Asia-Pacific Targeted Drugs for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 53. Asia-Pacific Targeted Drugs for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 54. Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2016-2021) & (US$ Million) 
    Table 55. Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2022-2027) & (US$ Million) 
    Table 56. Latin America Targeted Drugs for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 57. Latin America Targeted Drugs for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 58. Latin America Targeted Drugs for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 59. Latin America Targeted Drugs for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 60. Latin America Targeted Drugs for NSCLC Market Size by Country (2016-2021) & (US$ Million) 
    Table 61. Latin America Targeted Drugs for NSCLC Market Size by Country (2022-2027) & (US$ Million) 
    Table 62. Middle East & Africa Targeted Drugs for NSCLC Market Size by Type (2016-2021) (US$ Million)
    Table 63. Middle East & Africa Targeted Drugs for NSCLC Market Size by Type (2022-2027) & (US$ Million)
    Table 64. Middle East & Africa Targeted Drugs for NSCLC Market Size by Application (2016-2021) (US$ Million)
    Table 65. Middle East & Africa Targeted Drugs for NSCLC Market Size by Application (2022-2027) & (US$ Million)
    Table 66. Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2016-2021) & (US$ Million) 
    Table 67. Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2022-2027) & (US$ Million) 
    Table 68. Allergan Company Details
    Table 69. Allergan Business Overview
    Table 70. Allergan Targeted Drugs for NSCLC Product
    Table 71. Allergan Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 72. Allergan Recent Development
    Table 73. Amgen Company Details
    Table 74. Amgen Business Overview
    Table 75. Amgen Targeted Drugs for NSCLC Product
    Table 76. Amgen Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 77. Amgen Recent Development
    Table 78. ARIAD Pharmaceuticals (Takeda) Company Details
    Table 79. ARIAD Pharmaceuticals (Takeda) Business Overview
    Table 80. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product
    Table 81. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 82. ARIAD Pharmaceuticals (Takeda) Recent Development
    Table 83. Beacon Pharma Limited Company Details
    Table 84. Beacon Pharma Limited Business Overview
    Table 85. Beacon Pharma Limited Targeted Drugs for NSCLC Product
    Table 86. Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 87. Beacon Pharma Limited Recent Development
    Table 88. BeiGene Company Details
    Table 89. BeiGene Business Overview
    Table 90. BeiGene Targeted Drugs for NSCLC Product
    Table 91. BeiGene Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 92. BeiGene Recent Development
    Table 93. Biocon Company Details
    Table 94. Biocon Business Overview
    Table 95. Biocon Targeted Drugs for NSCLC Product
    Table 96. Biocon Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 97. Biocon Recent Development
    Table 98. Boehringer-Ingelheim Company Details
    Table 99. Boehringer-Ingelheim Business Overview
    Table 100. Boehringer-Ingelheim Targeted Drugs for NSCLC Product
    Table 101. Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 102. Boehringer-Ingelheim Recent Development
    Table 103. Celgene Corporation Company Details
    Table 104. Celgene Corporation Business Overview
    Table 105. Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 106. Celgene Corporation Recent Development
    Table 107. Drug International Limted Company Details
    Table 108. Drug International Limted Business Overview
    Table 109. Drug International Limted Targeted Drugs for NSCLC Product
    Table 110. Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 111. Drug International Limted Recent Development
    Table 112. Fujifilm Kyowa Kirin Biologics Company Details
    Table 113. Fujifilm Kyowa Kirin Biologics Business Overview
    Table 114. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product
    Table 115. Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 116. Fujifilm Kyowa Kirin Biologics Recent Development
    Table 117. Genvio Pharma Limited Company Details
    Table 118. Genvio Pharma Limited Business Overview
    Table 119. Genvio Pharma Limited Targeted Drugs for NSCLC Product
    Table 120. Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 121. Genvio Pharma Limited Recent Development
    Table 122. Hetero Drugs Company Details
    Table 123. Hetero Drugs Business Overview
    Table 124. Hetero Drugs Targeted Drugs for NSCLC Product
    Table 125. Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 126. Hetero Drugs Recent Development
    Table 127. ImClone Systems ‎(Eli Lilly) Company Details
    Table 128. ImClone Systems ‎(Eli Lilly) Business Overview
    Table 129. ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Product
    Table 130. ImClone Systems ‎(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 131. ImClone Systems ‎(Eli Lilly) Recent Development
    Table 132. Incepta Pharmaceuticals Company Details
    Table 133. Incepta Pharmaceuticals Business Overview
    Table 134. Incepta Pharmaceuticals Targeted Drugs for NSCLC Product
    Table 135. Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 136. Incepta Pharmaceuticals Recent Development
    Table 137. Mylan Company Details
    Table 138. Mylan Business Overview
    Table 139. Mylan Targeted Drugs for NSCLC Product
    Table 140. Mylan Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 141. Mylan Recent Development
    Table 142. Novartis Company Details
    Table 143. Novartis Business Overview
    Table 144. Novartis Targeted Drugs for NSCLC Product
    Table 145. Novartis Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 146. Novartis Recent Development
    Table 147. Pfizer Company Details
    Table 148. Pfizer Business Overview
    Table 149. Pfizer Targeted Drugs for NSCLC Product
    Table 150. Pfizer Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 151. Pfizer Recent Development
    Table 152. Reliance Lifesciences Company Details
    Table 153. Reliance Lifesciences Business Overview
    Table 154. Reliance Lifesciences Targeted Drugs for NSCLC Product
    Table 155. Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 156. Reliance Lifesciences Recent Development
    Table 157. Roche Company Details
    Table 158. Roche Business Overview
    Table 159. Roche Targeted Drugs for NSCLC Product
    Table 160. Roche Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 161. Roche Recent Development
    Table 162. AstraZeneca Company Details
    Table 163. AstraZeneca Business Overview
    Table 164. AstraZeneca Targeted Drugs for NSCLC Product
    Table 165. AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 166. AstraZeneca Recent Development
    Table 167. Cipla Company Details
    Table 168. Cipla Business Overview
    Table 169. Cipla Targeted Drugs for NSCLC Product
    Table 170. Cipla Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 171. Cipla Recent Development
    Table 172. Teva Company Details
    Table 173. Teva Business Overview
    Table 174. Teva Targeted Drugs for NSCLC Product
    Table 175. Teva Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 176. Teva Recent Development
    Table 177. OSI Pharmaceuticals Company Details
    Table 178. OSI Pharmaceuticals Business Overview
    Table 179. OSI Pharmaceuticals Targeted Drugs for NSCLC Product
    Table 180. OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 181. OSI Pharmaceuticals Recent Development
    Table 182. Glenmark Pharmaceuticals Company Details
    Table 183. Glenmark Pharmaceuticals Business Overview
    Table 184. Glenmark Pharmaceuticals Targeted Drugs for NSCLCProduct
    Table 185. Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 186. Glenmark Pharmaceuticals Recent Development
    Table 187. Natco Pharma Company Details
    Table 188. Natco Pharma Business Overview
    Table 189. Natco Pharma Targeted Drugs for NSCLC Product
    Table 190. Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2016-2021) & (US$ Million)
    Table 191. Natco Pharma Recent Development
    Table 192. Research Programs/Design for This Report
    Table 193. Key Data Information from Secondary Sources
    Table 194. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Targeted Drugs for NSCLC Market Share by Type: 2020 VS 2027
    Figure 2. Target EGFR Features
    Figure 3. Target ALK Features
    Figure 4. Target HER2 Features
    Figure 5. Target ROS1 Features
    Figure 6. Target BRAF Features
    Figure 7. Target MEK Features
    Figure 8. Target VEGFR2 Features
    Figure 9. Target VEGF Features
    Figure 10. Target MET Features
    Figure 11. Global Targeted Drugs for NSCLC Market Share by Application: 2020 VS 2027
    Figure 12. Squamous Cell Carcinoma of NSCLC Case Studies
    Figure 13. Adenocarcinoma of NSCLC Case Studies
    Figure 14. Large Cell Carcinoma of NSCLC Case Studies
    Figure 15. Targeted Drugs for NSCLC Report Years Considered
    Figure 16. Global Targeted Drugs for NSCLC Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 17. Global Targeted Drugs for NSCLC Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 18. Global Targeted Drugs for NSCLC Market Share by Regions: 2020 VS 2027
    Figure 19. Global Targeted Drugs for NSCLC Market Share by Regions (2022-2027)
    Figure 20. Global Targeted Drugs for NSCLC Market Share by Players in 2020
    Figure 21. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for NSCLC as of 2020
    Figure 22. The Top 10 and 5 Players Market Share by Targeted Drugs for NSCLC Revenue in 2020
    Figure 23. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2016-2021)
    Figure 24. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2022-2027)
    Figure 25. North America Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. North America Targeted Drugs for NSCLC Market Share by Type (2016-2027)
    Figure 27. North America Targeted Drugs for NSCLC Market Share by Application (2016-2027)
    Figure 28. North America Targeted Drugs for NSCLC Market Share by Country (2016-2027)
    Figure 29. United States Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. Canada Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. Europe Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Europe Targeted Drugs for NSCLC Market Share by Type (2016-2027)
    Figure 33. Europe Targeted Drugs for NSCLC Market Share by Application (2016-2027)
    Figure 34. Europe Targeted Drugs for NSCLC Market Share by Country (2016-2027)
    Figure 35. Germany Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. France Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. U.K. Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Italy Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Russia Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Nordic Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Asia-Pacific Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Asia-Pacific Targeted Drugs for NSCLC Market Share by Type (2016-2027)
    Figure 43. Asia-Pacific Targeted Drugs for NSCLC Market Share by Application (2016-2027)
    Figure 44. Asia-Pacific Targeted Drugs for NSCLC Market Share by Region (2016-2027)
    Figure 45. China Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Japan Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. South Korea Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Southeast Asia Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. India Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Australia Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Latin America Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Latin America Targeted Drugs for NSCLC Market Share by Type (2016-2027)
    Figure 53. Latin America Targeted Drugs for NSCLC Market Share by Application (2016-2027)
    Figure 54. Latin America Targeted Drugs for NSCLC Market Share by Country (2016-2027)
    Figure 55. Mexico Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Brazil Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Middle East & Africa Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Middle East & Africa Targeted Drugs for NSCLC Market Share by Type (2016-2027)
    Figure 59. Middle East & Africa Targeted Drugs for NSCLC Market Share by Application (2016-2027)
    Figure 60. Middle East & Africa Targeted Drugs for NSCLC Market Share by Country (2016-2027)
    Figure 61. Turkey Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 62. Saudi Arabia Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 63. UAE Targeted Drugs for NSCLC Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 64. Allergan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 65. Amgen Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 66. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 67. Beacon Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 68. BeiGene Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 69. Biocon Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 70. Boehringer-Ingelheim Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 71. Celgene Corporation Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 72. Drug International Limted Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 73. Fujifilm Kyowa Kirin Biologics Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 74. Genvio Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 75. Hetero Drugs Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 76. ImClone Systems ‎(Eli Lilly) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 77. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 78. Mylan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 79. Novartis Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 80. Pfizer Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 81. Reliance Lifesciences Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 82. Roche Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 83. AstraZeneca Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 84. Cipla Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 85. Teva Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 86. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 87. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 88. Natco Pharma Revenue Growth Rate in Targeted Drugs for NSCLC Business (2016-2021)
    Figure 89. Bottom-up and Top-down Approaches for This Report
    Figure 90. Data Triangulation
    Figure 91. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Allergan
Amgen
ARIAD Pharmaceuticals (Takeda)
Beacon Pharma Limited
BeiGene
Biocon
Boehringer-Ingelheim
Celgene Corporation
Drug International Limted
Fujifilm Kyowa Kirin Biologics
Genvio Pharma Limited
Hetero Drugs
ImClone Systems ‎(Eli Lilly)
Incepta Pharmaceuticals
Mylan
Novartis
Pfizer
Reliance Lifesciences
Roche
AstraZeneca
Cipla
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Natco Pharma
Frequently Asked Questions
Targeted Drugs for NSCLC report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Targeted Drugs for NSCLC report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Targeted Drugs for NSCLC report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports